<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03256552</url>
  </required_header>
  <id_info>
    <org_study_id>PT001004</org_study_id>
    <nct_id>NCT03256552</nct_id>
  </id_info>
  <brief_title>Study to Assess the Efficacy and Safety of Three Doses of PT001 in Japanese Subjects With Moderate to Severe COPD</brief_title>
  <official_title>A Randomized, Double-Blind, Chronic Dosing (7-Day), Four-Period, Four-Treatment, Placebo-Controlled, Cross-Over, Multi-Center Study to Assess the Efficacy and Safety of Three Doses of PT001 in Japanese Subjects With Moderate to Severe COPD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pearl Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pearl Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall objective of this study was to assess the efficacy and safety of GP MDI relative
      to placebo in Japanese subjects with moderate to severe COPD. Each subject received the 4
      separate study treatments, scheduled as four, 7-day, treatment periods for a total treatment
      duration of 28 days.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was a randomized, double-blind, chronic-dosing (7-day), four-period, four-treatment,
      placebo-controlled, crossover, multi-center study to assess the efficacy and safety of 3
      doses of GP MDI (28.8, 14.4, and 7.2 μg ex-actuator, BID) in Japanese subjects with moderate
      to severe COPD.

      Subjects who met the entry criteria had their maintenance therapy for COPD adjusted, as
      specified in the protocol. To allow for an adequate washout of previous maintenance
      medications, subjects underwent a washout period of at least 7 days, but not greater than 28
      days duration prior to returning to the clinic for Visit 2 (Randomization Visit; Day 1 of
      Treatment Period 1).

      The 4 study treatments were GP MDI 28.8, 14.4, and 7.2 μg ex-actuator, and Placebo MDI BID.
      Subjects were randomly assigned to 1 of the following 4 treatment sequences (ABCD, BDAC,
      CADB, DCBA) in a 1:1:1:1 ratio using an Interactive Web Response System where each letter
      represented 1 of the 4 treatments included in the study by random assignment.

      Subjects were to complete 7 days of dosing in each of the 4 Treatment Periods, with each
      Treatment Period separated by a washout period of 5 to 21 days.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 28, 2015</start_date>
  <completion_date type="Actual">September 5, 2015</completion_date>
  <primary_completion_date type="Actual">September 5, 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>randomized, double-blind, chronic-dosing (7-day), four-period, four-treatment, placebo-controlled, crossover, multi-center</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Morning Pre-dose Trough FEV1</measure>
    <time_frame>Baseline, Day 8</time_frame>
    <description>Change from Baseline in Morning Pre-dose Trough FEV1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>FEV1 AUC0-2</measure>
    <time_frame>Day 1 and Day 8</time_frame>
    <description>Change from Baseline in FEV1 AUC0-2 normalized for length of follow-up. FEV1 was measured at 15 min, 30 min, 1 hour, and 2 hours post dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Change in FEV1</measure>
    <time_frame>Day 1 and Day 8</time_frame>
    <description>Peak Change from Baseline in FEV1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FVC AUC0-2</measure>
    <time_frame>Baseline, Day 8</time_frame>
    <description>Change from Baseline in FVC AUC0-2 on Day 8 normalized for length of follow-up. FVC was measured at 15 min, 30 min, 1 hour, and 2 hours post dose.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">66</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>GP MDI 28.8 micrograms</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Glycopyrronium Metered Dose Inhaler 28.8 micrograms</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GP MDI 14.4 micrograms</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Glycopyrronium Metered Dose Inhaler 14.4 micrograms</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GP MDI 7.2 micrograms</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Glycopyrronium Metered Dose Inhaler 7.2 micrograms</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo MDI</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Inhalation Aerosol</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glycopyrronium MDI 28.8 micrograms</intervention_name>
    <description>Glycopyrronium MDI 28.8 micrograms</description>
    <arm_group_label>GP MDI 28.8 micrograms</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glycopyrronium MDI 14.4 micrograms</intervention_name>
    <description>Glycopyrronium MDI 14.4 micrograms</description>
    <arm_group_label>GP MDI 14.4 micrograms</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glycopyrronium MDI 7.2 micrograms</intervention_name>
    <description>Glycopyrronium MDI 7.2 micrograms</description>
    <arm_group_label>GP MDI 7.2 micrograms</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo MDI</intervention_name>
    <description>Placebo Inhalation Aerosol</description>
    <arm_group_label>Placebo MDI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical history of COPD with a moderate to severe classification

          -  Current and former smokers with a history of at least 10 pack-years of cigarette
             smoking.

        -Post-bronchodilator FEV1 must be ≥30% and &lt;80% predicted normal value-

        Exclusion Criteria:

          -  Pregnancy

          -  Primary asthma diagnosis; Poorly controlled COPD defined as acute worsening of COPD
             that required treatment with corticosteroids or antibiotics in the 6-week interval
             prior to Screening or between Screening and Visit 2;

          -  Clinically significant abnormal ECG

          -  Other active pulmonary disease such as active tuberculosis, lung cancer,
             bronchiectasis, sarcoidosis, lung fibrosis, primary pulmonary hypertension,
             interstitial lung disease, and uncontrolled sleep apnea; Cancer that was not in
             complete remission for at least 5 years;

          -  Diagnosis of angle closure glaucoma

          -  A documented myocardial infarction within 1 year of Screening.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Fukuoka-shi</city>
        <state>Fukuoka-Ken</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Iizuka-shi</city>
        <state>Fukuoka-Ken</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Mizunami-shi</city>
        <state>Gifu-Ken</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Sapporo-shi</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Ako-shi</city>
        <state>Hyogo-Ken</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Kakogawa-shi</city>
        <state>Hyogo-Ken</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Kobe-Shi</city>
        <state>Hyogo-Ken</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Nishinomiya-shi</city>
        <state>Hyogo-Ken</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Himeji-shi</city>
        <state>Hyogo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Naka-gun</city>
        <state>Ibaraki-Ken</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Kawasaki-shi</city>
        <state>Kanagawa-Ken</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Kyoto-shi</city>
        <state>Kyoto-Fu</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Kasaoka-shi</city>
        <state>Okayama-Ken</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Kishiwada-shi</city>
        <state>Osaka-Fu</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Osaka-shi</city>
        <state>Osaka-Fu</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Hamamatsu-shi</city>
        <state>Shizuoka-Ken</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Chuo-ku</city>
        <state>Tokyo-To</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Toshima-ku</city>
        <state>Tokyo-To</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 17, 2017</study_first_submitted>
  <study_first_submitted_qc>August 17, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 22, 2017</study_first_posted>
  <results_first_submitted>November 13, 2017</results_first_submitted>
  <results_first_submitted_qc>December 22, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">January 23, 2018</results_first_posted>
  <last_update_submitted>December 22, 2017</last_update_submitted>
  <last_update_submitted_qc>December 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Conducted at 20 sites in Japan from January-September 2015. Entire period of study participation per subject was a maximum of 19 weeks. Planned target enrollment of 60 subjects.</recruitment_details>
      <pre_assignment_details>This was a chronic dosing (7 days), 4-period, 4-treatment, placebo-controlled, crossover study. Each subject was randomized to 1 of 4 sequences. Each sequence included the four treatment groups. By-treatment sequence tabulations of the data were not pre-specified.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Overall Study</title>
          <description>All Subjects Randomized</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="66"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>GP MDI 28.8 µg</title>
              <participants_list>
                <participants group_id="P1" count="61"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>GP MDI 14.4 µg</title>
              <participants_list>
                <participants group_id="P1" count="63"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>GP MDI 7.2 µg</title>
              <participants_list>
                <participants group_id="P1" count="62"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Placebo MDI</title>
              <participants_list>
                <participants group_id="P1" count="65"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="61"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>MITT Population defined as all subjects who received treatment and had post-treatment efficacy data from at least two treatment periods.</population>
      <group_list>
        <group group_id="B1">
          <title>All Subjects</title>
          <description>All Subjects in the MITT Population</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="62"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.5" spread="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Morning Pre-dose Trough FEV1</title>
        <description>Change from Baseline in Morning Pre-dose Trough FEV1</description>
        <time_frame>Baseline, Day 8</time_frame>
        <population>MITT Population defined as all subjects who received treatment and had post-treatment efficacy data from at least two treatment periods.</population>
        <group_list>
          <group group_id="O1">
            <title>GP MDI 28.8 µg</title>
            <description>Glycopyrronium MDI 28.8 µg</description>
          </group>
          <group group_id="O2">
            <title>GP MDI 14.4 µg</title>
            <description>Glycopyrronium 14.4 µg</description>
          </group>
          <group group_id="O3">
            <title>GP MDI 7.2 µg</title>
            <description>Glycopyrronium 7.2 µg</description>
          </group>
          <group group_id="O4">
            <title>Placebo MDI</title>
            <description>Placebo MDI</description>
          </group>
        </group_list>
        <measure>
          <title>Morning Pre-dose Trough FEV1</title>
          <description>Change from Baseline in Morning Pre-dose Trough FEV1</description>
          <population>MITT Population defined as all subjects who received treatment and had post-treatment efficacy data from at least two treatment periods.</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="61"/>
                <count group_id="O3" value="62"/>
                <count group_id="O4" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.101" lower_limit="0.068" upper_limit="0.134"/>
                    <measurement group_id="O2" value="0.098" lower_limit="0.066" upper_limit="0.131"/>
                    <measurement group_id="O3" value="0.077" lower_limit="0.045" upper_limit="0.110"/>
                    <measurement group_id="O4" value="-0.031" lower_limit="-0.064" upper_limit="0.002"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FEV1 AUC0-2</title>
        <description>Change from Baseline in FEV1 AUC0-2 normalized for length of follow-up. FEV1 was measured at 15 min, 30 min, 1 hour, and 2 hours post dose.</description>
        <time_frame>Day 1 and Day 8</time_frame>
        <population>MITT Population defined as all subjects who received treatment and had post-treatment efficacy data from at least two treatment periods.</population>
        <group_list>
          <group group_id="O1">
            <title>GP MDI 28.8 µg</title>
            <description>Glycopyrronium MDI 28.8 µg</description>
          </group>
          <group group_id="O2">
            <title>GP MDI 14.4 µg</title>
            <description>Glycopyrronium 14.4 µg</description>
          </group>
          <group group_id="O3">
            <title>GP MDI 7.2 µg</title>
            <description>Glycopyrronium 7.2 µg</description>
          </group>
          <group group_id="O4">
            <title>Placebo MDI</title>
            <description>Placebo MDI</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 AUC0-2</title>
          <description>Change from Baseline in FEV1 AUC0-2 normalized for length of follow-up. FEV1 was measured at 15 min, 30 min, 1 hour, and 2 hours post dose.</description>
          <population>MITT Population defined as all subjects who received treatment and had post-treatment efficacy data from at least two treatment periods.</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="61"/>
                <count group_id="O3" value="62"/>
                <count group_id="O4" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.176" lower_limit="0.146" upper_limit="0.205"/>
                    <measurement group_id="O2" value="0.140" lower_limit="0.111" upper_limit="0.170"/>
                    <measurement group_id="O3" value="0.127" lower_limit="0.098" upper_limit="0.157"/>
                    <measurement group_id="O4" value="0.043" lower_limit="0.014" upper_limit="0.073"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.194" lower_limit="0.157" upper_limit="0.230"/>
                    <measurement group_id="O2" value="0.199" lower_limit="0.162" upper_limit="0.236"/>
                    <measurement group_id="O3" value="0.170" lower_limit="0.133" upper_limit="0.206"/>
                    <measurement group_id="O4" value="0.019" lower_limit="-0.018" upper_limit="0.055"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak Change in FEV1</title>
        <description>Peak Change from Baseline in FEV1</description>
        <time_frame>Day 1 and Day 8</time_frame>
        <population>MITT Population defined as all subjects who received treatment and had post-treatment efficacy data from at least two treatment periods.</population>
        <group_list>
          <group group_id="O1">
            <title>GP MDI 28.8 µg</title>
            <description>Glycopyrronium MDI 28.8 µg</description>
          </group>
          <group group_id="O2">
            <title>GP MDI 14.4 µg</title>
            <description>Glycopyrronium 14.4 µg</description>
          </group>
          <group group_id="O3">
            <title>GP MDI 7.2 µg</title>
            <description>Glycopyrronium 7.2 µg</description>
          </group>
          <group group_id="O4">
            <title>Placebo MDI</title>
            <description>Placebo MDI</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Change in FEV1</title>
          <description>Peak Change from Baseline in FEV1</description>
          <population>MITT Population defined as all subjects who received treatment and had post-treatment efficacy data from at least two treatment periods.</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="61"/>
                <count group_id="O3" value="62"/>
                <count group_id="O4" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.254" lower_limit="0.219" upper_limit="0.289"/>
                    <measurement group_id="O2" value="0.212" lower_limit="0.177" upper_limit="0.247"/>
                    <measurement group_id="O3" value="0.192" lower_limit="0.157" upper_limit="0.227"/>
                    <measurement group_id="O4" value="0.104" lower_limit="0.069" upper_limit="0.139"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.260" lower_limit="0.219" upper_limit="0.301"/>
                    <measurement group_id="O2" value="0.265" lower_limit="0.224" upper_limit="0.306"/>
                    <measurement group_id="O3" value="0.238" lower_limit="0.197" upper_limit="0.279"/>
                    <measurement group_id="O4" value="0.082" lower_limit="0.041" upper_limit="0.124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FVC AUC0-2</title>
        <description>Change from Baseline in FVC AUC0-2 on Day 8 normalized for length of follow-up. FVC was measured at 15 min, 30 min, 1 hour, and 2 hours post dose.</description>
        <time_frame>Baseline, Day 8</time_frame>
        <population>MITT Population defined as all subjects who received treatment and had post-treatment efficacy data from at least two treatment periods.</population>
        <group_list>
          <group group_id="O1">
            <title>GP MDI 28.8 µg</title>
            <description>Glycopyrronium MDI 28.8 µg</description>
          </group>
          <group group_id="O2">
            <title>GP MDI 14.4 µg</title>
            <description>Glycopyrronium 14.4 µg</description>
          </group>
          <group group_id="O3">
            <title>GP MDI 7.2 µg</title>
            <description>Glycopyrronium 7.2 µg</description>
          </group>
          <group group_id="O4">
            <title>Placebo MDI</title>
            <description>Placebo MDI</description>
          </group>
        </group_list>
        <measure>
          <title>FVC AUC0-2</title>
          <description>Change from Baseline in FVC AUC0-2 on Day 8 normalized for length of follow-up. FVC was measured at 15 min, 30 min, 1 hour, and 2 hours post dose.</description>
          <population>MITT Population defined as all subjects who received treatment and had post-treatment efficacy data from at least two treatment periods.</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="61"/>
                <count group_id="O3" value="62"/>
                <count group_id="O4" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.273" lower_limit="0.207" upper_limit="0.339"/>
                    <measurement group_id="O2" value="0.265" lower_limit="0.199" upper_limit="0.331"/>
                    <measurement group_id="O3" value="0.223" lower_limit="0.157" upper_limit="0.288"/>
                    <measurement group_id="O4" value="0.047" lower_limit="-0.019" upper_limit="0.113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected from the time the subject signed consent up to the follow-up visit 7-14 days after last dose of study drug.</time_frame>
      <desc>Safety population included all participants who received at least one dose of investigational drug and had safety data available; participants were included in safety population according to the investigational drug received</desc>
      <group_list>
        <group group_id="E1">
          <title>GP MDI 28.8 µg</title>
          <description>Glycopyrronium MDI 28.8 µg</description>
        </group>
        <group group_id="E2">
          <title>GP MDI 14.4 µg</title>
          <description>Glycopyrronium 14.4 µg</description>
        </group>
        <group group_id="E3">
          <title>GP MDI 7.2 µg</title>
          <description>Glycopyrronium 7.2 µg</description>
        </group>
        <group group_id="E4">
          <title>Placebo MDI</title>
          <description>Placebo MDI</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic Obstructive Pulmonary Disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="61"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Drafts of any and all publications or presentations of this study must be submitted at least 30 days prior to submission for publication or presentation to Pearl Therapeutics for review, approval, and to ensure consistency. Pearl Therapeutics has the right to request appropriate modification to correct facts and to represent its opinions, or the opinions of the publication committee, if these differ with the proposed publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Colin Reisner, MD, FCCP, FAAAAI</name_or_title>
      <organization>Pearl Therapeutics, Inc</organization>
      <phone>650-305-2600</phone>
      <email>creisner@pearltherapeutics.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

